37.92
  Price8.58%   -3.56
(Pre-market: .00 -37.92 -100.00%)
Nov-09-21 07:05AM Veracyte (VCYT) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research
08:13AM The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug DataBenzinga
Nov-02-21 03:01AM Earnings Preview: Veracyte (VCYT) Q3 Earnings Expected to DeclineZacks Investment Research
Sep-15-21 07:38AM The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOsBenzinga
Aug-07-21 09:44AM 20 cloud stocks expected to increase sales the most over the next two yearsMarketWatch
Aug-06-21 07:06AM 20 cloud stocks expected to increase sales the most over the next two yearsMarketWatch
Aug-05-21 02:04AM 20 cloud stocks expected to increase sales the most over the next two yearsMarketWatch
Jul-29-21 08:15AM The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOsBenzinga
06:55AM After Naming a New CFO, Is This Genetic Diagnostics Company a Buy?The Motley Fool
Jul-25-21 09:26AM The Week Ahead In Biotech: Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and MoreBenzinga
Jul-22-21 03:03AM Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to DeclineZacks Investment Research
Jun-15-21 10:24AM Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021Benzinga
Jun-09-21 07:18AM Moving Average Crossover Alert: Veracyte (VCYT)Zacks Investment Research
Veracyte, Inc. operates as a genomic diagnostics company in the United States. The company uses genomic technology to resolve diagnostic uncertainty. It offers Afirma Thyroid FNA Analysis solution; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients. The company's products also include Percepta Bronchial Genomic Classifier solution for use in lung cancer screening and diagnosis; and Envisia Genomic Classifier solution for idiopathic pulmonary fibrosis. Veracyte, Inc. sells its products through product specialists, institutional managers, account managers, and medical science specialists. Veracyte, Inc. has research collaboration agreement with Loxo Oncology to develop medicines for patients with genetically defined cancers. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Cap:    |  Volume (24h):